Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: An analysis of the FDA adverse event reporting system

Inflammatory Bowel Diseases

Volumn 19, Issue 6, 2013, Pages 1164-1172

  Kip, Kevin E ^a   Swoger, Jason M ^b,c   Grandinetti, Lisa M ^b,c   Barrie III, Arthur M ^b   Greer, Julia B ^b   Regueiro, Miguel D ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adverse events; Crohn's disease; Infliximab; Psoriasis; TNF antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LITHIUM CARBONATE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; PLAQUERIL; PROPRANOLOL; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; CALCULATION; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG DATABASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYETHYLENE GLYCOLS; PROGNOSIS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84879205644     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828075bd     Document Type: Review

References (50)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
2. Rutgeerts P, Vermeire S, van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56: 453-455.
3. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438.
4. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231:38-45.
5. Panaccione R, Rutgeerts P, Sandborn WJ, et al. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688.
6. Feagan BG, Le'mann M, Befrits R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis. 2012;18:152-160.
7. Kamm MA, Ng SC, De Cruz P, et al. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis. 2011;17:2366-2391.
8. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2008;CD006893.
9. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol Suppl. 2002;65:33-38.
10. Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002;8:186-191.
11. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-215.
12. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitorinduced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1-14.
13. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055.
14. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385-390.
15. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets. 2007;11:1369-1384.
16. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by antitumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
17. Klein RQ, Spivack J, Choate KA. Psoriatic skin lesions induced by certolizumab pegol. Arch Dermatol. 2010;146:1055-1056.
18. U.S. Dept. of Health and Human Services. The Adverse Event Reporting System (AERS): Latest Quarterly Data Files. Available at: http://www.fda.gov/ Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ ucm082193.htm. Accessed February 12, 2012.
19. Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729-735.
20. Kadoyama K, Kuwahara A, Yamamori M, et al. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res. 2011;30:93.
21. Kadoyama K, Miki I, Tamura T, et al. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. Int J Med Sci. 2012;9:33-39.
22. Jones SC, Sorbello A, Boucher RM. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011;34:839-847.
23. Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One. 2011;6:e28124.
24. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004; 31:1955-1958.
25. U.S. Department of Health and Human Services. Adverse Event Reporting System (AERS). Available at: http://www.fda.gov/Drugs/GuidanceCom- plianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed February 18, 2012.
26. Welcome to MedDRA and the MSSO. Available at: http://www.meddramsso.com/. Accessed February 20, 2012.
27. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993; 269:2765-2768.
28. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140:795-801.
29. Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci. 2011;8:487-491.
30. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427-436.
31. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol. 1999;455: 221-225.
32. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemioloy Drug Saf. 2001;10:483-486.
33. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-240.
34. Glenn CJ, Kobraei KB, Russo JJ. New-onset psoriasis associated with adalimumab: a report of two cases. Dermatol Online J. 2011;17:15.
35. Laga AC, Vleugels RA, Qureshi AA, et al. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010;32:568-573.
36. Lowes MA, Chamian F, Abello MV, et al. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol. 2007;7:2.
37. Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol. 2007;32:176-179.
38. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-231.
39. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:230-232.
40. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol. 2009;23:561-565.
41. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805-821; quiz 22-24.
42. Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn's disease and ulcerative colitis. Br J Dermatol. 1982;106:323-330.
43. Aeberli D, Seitz M, Juni P, et al. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford). 2005;44:172-175.
44. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol. 2009;161:1081-1088.
45. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005; 202:135-143.
46. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582.
47. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
48. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
49. Sakaeda T, Kadoyama K, Yabuuchi H, et al. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2011;8:332-338.
50. Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol. [published online ahead of print October 19, 2011]. doi: 10.1007/s00592-011-0340-7.